Covalent inhibitors typically target a specific amino acid residue within the active site of a protein. The most commonly targeted residue is cysteine due to its nucleophilic thiol side chain. The inhibitor forms a covalent bond with this residue, effectively "shutting down" the protein's function. This mechanism ensures prolonged inhibition, which can be beneficial in targeting rapidly dividing cancer cells.
